Provided by Tiger Trade Technology Pte. Ltd.

Skye Bioscience Inc.

1.69
+0.01000.60%
Post-market: 1.65-0.0400-2.37%17:25 EDT
Volume:18.52K
Turnover:31.60K
Market Cap:7.42M
PE:-0.17
High:1.77
Open:1.69
Low:1.67
Close:1.68
52wk High:14.08
52wk Low:1.50
Shares:4.39M
Float Shares:2.87M
Volume Ratio:0.59
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.2399
EPS(LYR):-11.2801
ROE:-233.87%
ROA:-95.06%
PB:-14.92
PE(LYR):-0.15

Loading ...

Skye Bioscience - Post Deal Skye to Own 5.38% of Combined Co with Holding Redx 46.17%, Financing Investors 48.45%

THOMSON REUTERS
·
Aug 14

Skye Bioscience - Peter Collum to Serve as CFO of Fibrx Therapeutics

THOMSON REUTERS
·
Aug 14

Skye Bioscience - Combined Company to Operate as Fibrx Therapeutics and Trade on NASDAQ

THOMSON REUTERS
·
Aug 14

Skye Bioscience - to Buy Entire Issued Share Capital of Redx

THOMSON REUTERS
·
Aug 14

NASDAQ Trade Halt Halt News Pending at 08:39 Am

Reuters
·
Aug 14

Skye Bioscience Inc Expected to Post a Loss of 25 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Skye Bioscience Lawsuit: MFDI Seeks Dismissal of Securities Claims Against It

TIPRANKS
·
Jul 30

Skye Bioscience Lawsuit: Company and CEO Move to Dismiss Claims

TIPRANKS
·
Jul 24

Cadrenal Therapeutics Names John P. Sharp Interim CFO, Replacing Quang X. Pham

Reuters
·
Jun 30

SkyeChip Signs Deal for ARM Flexible Access Token Under MIDA Program

MT Newswires Live
·
Jun 24

Skye Bioscience transfers Nasdaq listing to Capital Market tier effective June 23

Reuters
·
Jun 23

Skye Bioscience raises authorized common shares to 300,000,000 from 100,000,000

Reuters
·
May 30

Skye Bioscience opens higher-dose Cohort 2 in nimacimab obesity Phase 2a study

Reuters
·
May 20

UOB Kay Hian Starts SkyeChip at Buy with MYR2.08 Price Target

MT Newswires Live
·
May 20

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data From First Four Participants Treated in Cohort 1

THOMSON REUTERS
·
May 20

Skye Bioscience Inc - Crc Approves Enrollment in Cohort 2 (600 Mg Iv) After Favorable Safety Review of Cohort 1

THOMSON REUTERS
·
May 20

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

GlobeNewswire
·
May 20

Skye Bioscience receives Nasdaq notice for falling below $10 million equity minimum

Reuters
·
May 16

Skye Bioscience posts corporate presentation on nimacimab obesity drug development strategy

Reuters
·
May 13

Update – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

THOMSON REUTERS
·
May 13